Strides Pharma [STAR] vs Alembic [APLLTD] Detailed Stock Comparison
Strides Pharma
NSE
Loading...
Alembic
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Strides Pharma wins in 13 metrics, Alembic wins in 7 metrics, with 0 ties. Strides Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Strides Pharma | Alembic | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 21.92 | 30.50 | Strides Pharma |
| Price-to-Book Ratio | 2.94 | 3.55 | Strides Pharma |
| Debt-to-Equity Ratio | 72.67 | 24.23 | Alembic |
| PEG Ratio | 12.64 | 21.52 | Strides Pharma |
| EV/EBITDA | 11.48 | 19.27 | Strides Pharma |
| Profit Margin (TTM) | 7.38% | 8.84% | Alembic |
| Operating Margin (TTM) | 15.11% | 12.13% | Strides Pharma |
| EBITDA Margin (TTM) | 15.11% | 12.13% | Strides Pharma |
| Return on Equity | 138.93% | 11.24% | Strides Pharma |
| Return on Assets (TTM) | 59.41% | 7.51% | Strides Pharma |
| Free Cash Flow (TTM) | $4.42B | $-4.76B | Strides Pharma |
| Dividend Yield | 0.74% | 1.09% | Alembic |
| 1-Year Return | -29.61% | -15.92% | Alembic |
| Price-to-Sales Ratio (TTM) | 1.63 | 2.70 | Strides Pharma |
| Enterprise Value | $90.73B | $198.53B | Alembic |
| EV/Revenue Ratio | 1.96 | 2.91 | Strides Pharma |
| Gross Profit Margin (TTM) | 60.32% | 76.18% | Alembic |
| Revenue per Share (TTM) | $503 | $347 | Strides Pharma |
| Earnings per Share (Diluted) | $37.12 | $30.70 | Strides Pharma |
| Beta (Stock Volatility) | 0.57 | 0.47 | Alembic |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Strides Pharma vs Alembic Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Strides Pharma | 0.76% | -3.84% | -7.07% | 26.63% | 9.57% | 14.21% |
| Alembic | -1.49% | -2.38% | -6.43% | 3.77% | 5.42% | -10.75% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Strides Pharma | -29.61% | 130.32% | 44.47% | -33.73% | 100.09% | 182.26% |
| Alembic | -15.92% | 45.65% | -8.45% | 35.15% | 1,943.76% | 1,943.76% |
Performance & Financial Health Analysis: Strides Pharma vs Alembic
| Metric | STAR | APLLTD |
|---|---|---|
| Market Information | ||
| Market Cap | ₹75.67B | ₹184.02B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 624,765 | 120,577 |
| 90 Day Avg. Volume | 495,285 | 673,724 |
| Last Close | ₹804.40 | ₹936.20 |
| 52 Week Range | ₹513.05 - ₹1,675.00 | ₹725.20 - ₹1,303.90 |
| % from 52W High | -51.98% | -28.20% |
| All-Time High | ₹1,675.00 (Oct 14, 2024) | ₹1,303.90 (Oct 07, 2024) |
| % from All-Time High | -51.98% | -28.20% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.03% | 0.10% |
| Quarterly Earnings Growth | 0.42% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.09% |
| Operating Margin (TTM) | 0.15% | 0.12% |
| Return on Equity (TTM) | 1.39% | 0.11% |
| Debt to Equity (MRQ) | 72.67 | 24.23 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹276.88 | ₹264.09 |
| Cash per Share (MRQ) | ₹21.55 | ₹4.25 |
| Operating Cash Flow (TTM) | ₹36.02B | ₹-3,101,700,000 |
| Levered Free Cash Flow (TTM) | ₹35.93B | ₹5.83B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.74% | 1.09% |
| Last 12-Month Dividend | ₹6.50 | ₹11.00 |
Valuation & Enterprise Metrics Analysis: Strides Pharma vs Alembic
| Metric | STAR | APLLTD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 21.92 | 30.50 |
| Forward P/E | 12.64 | 21.52 |
| PEG Ratio | 12.64 | 21.52 |
| Price to Sales (TTM) | 1.63 | 2.70 |
| Price to Book (MRQ) | 2.94 | 3.55 |
| Market Capitalization | ||
| Market Capitalization | ₹75.67B | ₹184.02B |
| Enterprise Value | ₹90.73B | ₹198.53B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.96 | 2.91 |
| Enterprise to EBITDA | 11.48 | 19.27 |
| Risk & Other Metrics | ||
| Beta | 0.57 | 0.47 |
| Book Value per Share (MRQ) | ₹276.88 | ₹264.09 |
Financial Statements Comparison: Strides Pharma vs Alembic
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | STAR | APLLTD |
|---|---|---|
| Revenue/Sales | ₹11.20B | ₹17.70B |
| Cost of Goods Sold | ₹4.44B | ₹5.31B |
| Gross Profit | ₹6.75B | ₹12.39B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹1.69B | ₹2.03B |
| EBITDA | ₹2.27B | ₹2.85B |
| Pre-Tax Income | ₹1.22B | ₹1.92B |
| Income Tax | ₹164.50M | ₹353.10M |
| Net Income (Profit) | ₹1.06B | ₹1.57B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | STAR | APLLTD |
|---|---|---|
| Cash & Equivalents | ₹1.13B | ₹834.80M |
| Total Current Assets | ₹31.02B | ₹40.88B |
| Total Current Liabilities | ₹25.92B | ₹23.93B |
| Long-Term Debt | ₹6.23B | ₹467.70M |
| Total Shareholders Equity | ₹25.86B | ₹51.90B |
| Retained Earnings | ₹4.59B | N/A |
| Property, Plant & Equipment | ₹8.81B | ₹25.24B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | STAR | APLLTD |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | STAR | APLLTD |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 624,765 | 120,577 |
| Average Daily Volume (90 Day) | 495,285 | 673,724 |
| Shares Outstanding | 92.16M | 196.56M |
| Float Shares | 56.69M | 57.33M |
| % Held by Insiders | 0.33% | 0.70% |
| % Held by Institutions | 0.25% | 0.17% |
Dividend Analysis & Yield Comparison: Strides Pharma vs Alembic
| Metric | STAR | APLLTD |
|---|---|---|
| Last 12-Month Dividend | ₹6.50 | ₹11.00 |
| Last 12-Month Dividend Yield | 0.74% | 1.09% |
| 3-Year Avg Annual Dividend | ₹2.67 | ₹13.33 |
| 3-Year Avg Dividend Yield | 0.32% | 1.17% |
| 3-Year Total Dividends | ₹8.00 | ₹40.00 |
| Ex-Dividend Date | Jul 22, 2025 | Jul 29, 2025 |